AstraZeneca PLC (AZN) And Bristol-Myers Squibb Company (BMY) Release: Xigduo™ (Dapagliflozin And Metformin Hydrochloride) Receives Positive CHMP Opinion In The European Union For The Treatment Of Type 2 Diabetes
11/22/2013 10:13:56 AM
LONDON & PRINCETON, N.J.--(BUSINESS WIRE)--AstraZeneca (NYSE:AZN) and Bristol-Myers Squibb (NYSE:BMY) today announced that the Committee for Medicinal Products for Human Use (CHMP) of the European Medicines Agency (EMA) has adopted a positive opinion recommending approval of Xigduo™ (dapagliflozin and metformin hydrochloride) for adults aged 18 and older with type 2 diabetes mellitus as an adjunct to diet and exercise to improve glycaemic control in patients inadequately controlled on their current metformin-based treatment regimen or who are currently being treated with the combination of dapagliflozin and metformin as separate tablets.
Help employers find you! Check out all the jobs and post your resume.
comments powered by